Health Sciences Research Awards and Grants
* Award dollars are not included in the clinical trials, as funds are earned based upon completion of study milestones and enrollment.
| Title | Type | $ Amount | Activity | Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifera | Contract | * | Clinical Trial | Amy Sussman | Medicine | Apellis Pharmaceuticals | 06/2024 |
| A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clin | Contract | * | Clinical Trial | Sasha Taleban | Medicine | Celgene Corporation | 11/2023 |
| A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gen | Contract | * | Clinical Trial | Paul Larson | Neurosurgery | UniQure | 01/2024 |
| A Phase Ia.Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advance or Metastatic Solid Tumors | Contract | * | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Boehringer Ingelheim Pharmaceuticals, Inc | 09/2024 |
| A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Fact | Contract | * | Clinical Trial | Umbreen Rozell | Cancer Center Division | Astrazeneca | 11/2024 |
| A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator's Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/ | Contract | * | Clinical Trial | Junaid Arshad | Cancer Center Division | Astrazeneca | 09/2024 |
| A Phase III, Double-blind, Randomized Placebo-Controlled Study To Evaluate The Effects Of Dalcetrapib On Cardiovascular (CV) Risk In A Genetically Defined Population With A Recent Acute Coronary Syndr | Contract | * | Clinical Trial | Madhan Shanmugasundaram | Sarver Heart Center | Dalcor Pharmaceuticals (Canada) | 10/2024 |
| A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEV | Contract | * | Clinical Trial | Sasha Taleban | Medicine | Syneos Health | 04/2025 |
| A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infec | Contract | * | Clinical Trial | Christian Bime | Medicine | Astrazeneca | 11/2023 |
| A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the | Contract | * | Clinical Trial | Ricklie Julian | Cancer Center Division | Astrazeneca | 05/2025 |
| A Phase IIIb, Randomized, Multicenter, Open-label Study To Assess The Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab In Combination With Platinum-Based Chemotherapy For First-Line Treat | Contract | * | Clinical Trial | Linda Garland | Cancer Center Division | Astrazeneca | 02/2025 |
| A Phase Ill, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of a Single Administration Of Comp360 in Participants With Treatment- | Contract | * | Clinical Trial | Francisco Moreno | Senior VP Health Sciences | Icon Clinical Research, Incorporated | 07/2024 |
| A Post-market Multi-center Prospective Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss in Women Receiving Specific Chemotherapy Regimens for Breast Cancer | Contract | * | Clinical Trial | Sima Ehsani Chimeh | Cancer Center Division | Cooler Heads Care, Inc. | 10/2024 |
| A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation | Contract | * | Clinical Trial | Wilber Su | COM Phx Internal Medicine | Boston Scientific Corporation | 06/2024 |
| A Prospective, Open Label, Single-Arm, Multi-Center Study Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment Of Osteochondral Lesions in the Knee | Contract | * | Clinical Trial | Thomas Carter | COM Phx Orthopedics | AlloSource | 04/2024 |
| A Randomized Controlled Trial to Evaluate the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose at Increased Risk of Liver Injury | Contract | * | Clinical Trial | Farshad Shirazi | Dept of Emergency Medicine | Denver Health and Hospital Authority | 01/2024 |
| A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women with ER+/HER2- Breast Cancer | Contract | * | Clinical Trial | Sima Ehsani Chimeh | Cancer Center Division | Atossa Therapeutics | 03/2024 |
| A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pln-74809 (Bexotegrast) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF) | Contract | * | Clinical Trial | Sachin Chaudhary | Medicine | Pliant Therapeutics, Inc. | 03/2024 |
| A Randomized, Double-blind, Multicenter Phase Iii Study To Evaluate The Long-term Efficacy And Safety Of Abx464 25 Mg Or 50 Mg Once Daily As A Maintenance Therapy In Subjects With Moderately To Severe | Contract | * | Clinical Trial | Sasha Taleban | Medicine | Abivax (France) | 10/2024 |
| A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Phase III Study To Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of | Contract | * | Clinical Trial | Ricklie Julian | Cancer Center Division | IQVIA RDS Inc. | 03/2025 |
* Award dollars are not included in the clinical trials, as funds are earned based upon completion of study milestones and enrollment.